About Heron Therapeutics (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NASDAQ:HRTX
- CUSIP: N/A
- Web: www.herontx.com
- 50 Day Moving Avg: $14.75
- 200 Day Moving Avg: $14.57
- 52 Week Range: $12.21 - $24.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.37
- P/E Growth: 0.20
- Return on Equity: -218.39%
- Return on Assets: -144.10%
- Debt-to-Equity Ratio: 2.80%
- Current Ratio: 3.04%
- Quick Ratio: 2.98%
- Average Volume: 695,570 shs.
- Beta: 1.58
Frequently Asked Questions for Heron Therapeutics (NASDAQ:HRTX)
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics Inc (NASDAQ:HRTX) posted its earnings results on Wednesday, May, 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $1.96 million. View Heron Therapeutics' Earnings History.
Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2017?
10 analysts have issued 1-year price targets for Heron Therapeutics' stock. Their predictions range from $21.00 to $45.00. On average, they expect Heron Therapeutics' stock price to reach $34.50 in the next year. View Analyst Ratings for Heron Therapeutics.
What are analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Expensive 1Q: HRTX reported 1Q17 EPS of ($1.00), below our estimated ($0.83). The difference is mainly attributed to higher than expected R&D spend, though we believe that should taper off through the year, providing some flexibility in cash runway. HRTX finished the quarter with $165M in cash." (5/11/2017)
- 2. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/9/2017)
- 3. Needham & Company LLC analysts commented, "We initiate coverage of Heron Therapeutics, a commercial-stage specialty biopharma focused on novel extended-release injectables, at Buy with a $28 PT. HRTX made the transition to a commercial co. in 4Q16 with the launch of Sustol for CINV. Cinvanti, on file with FDA (likely 4Q17 PDUFA), will round out the CINV franchise. The main value driver, HTX-011, is an extended-release combination of bupivacaine/meloxicam in development for post-op pain management. HTX-011 successfully completed a comprehensive ph 2 program in various surgical procedures demonstrating superior efficacy to placebo and bupivacaine. HTX-011 will begin ph 3 development in 2017. Our valuation looks at the differentiated CINV assets and cash balance (~$215MM) as a floor value for HRTX, while the potential of HTX-011 remains mostly undervalued." (2/27/2017)
- 4. Cowen and Company analysts commented, "Yesterday Heron released positive Ph 2 abdominoplasty data for HTX-011." (1/6/2017)
Are investors shorting Heron Therapeutics?
Heron Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 19,980,369 shares, an increase of 1.5% from the March 31st total of 19,694,016 shares. Based on an average trading volume of 595,815 shares, the short-interest ratio is currently 33.5 days.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Johnson & Johnson (JNJ), Novartis AG (NVS), Pfizer (PFE), Merck & Co. (MRK), Sanofi SA (SNY), GlaxoSmithKline plc (GSK), AbbVie (ABBV), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Eli Lilly and Co (LLY), Shire PLC (SHPG), GW Pharmaceuticals PLC- (GWPH), Aerie Pharmaceuticals (AERI), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Retrophin (RTRX), Assembly Biosciences (ASMB) and Rockwell Medical (RMTI).
Who owns Heron Therapeutics stock?
Heron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (0.00%), FMR LLC (0.00%), Janus Capital Management LLC (0.00%), Broadfin Capital LLC (0.00%), Kingdon Capital Management L.L.C. (0.00%) and Vanguard Group Inc. (0.00%). Company insiders that own Heron Therapeutics stock include Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.
Who sold Heron Therapeutics stock? Who is selling Heron Therapeutics stock?
Heron Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., Morgan Stanley, UBS Group AG, KCG Holdings Inc. and California Public Employees Retirement System. Company insiders that have sold Heron Therapeutics stock in the last year include Kimberly Manhard and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.
Who bought Heron Therapeutics stock? Who is buying Heron Therapeutics stock?
Heron Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, FMR LLC, Citadel Advisors LLC, Rubric Capital Management LP, Broadfin Capital LLC, Janus Capital Management LLC, Vanguard Group Inc. and State Street Corp. View Insider Buying and Selling for Heron Therapeutics.
How do I buy Heron Therapeutics stock?
Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Heron Therapeutics stock cost?
One share of Heron Therapeutics stock can currently be purchased for approximately $14.20.
Earnings History for Heron Therapeutics (NASDAQ:HRTX)Earnings History by Quarter for Heron Therapeutics (NASDAQ:HRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 2017||($0.94)||($1.00)||$1.96 million||$3.63 million||View||N/A|
|2/23/2017||Q4 2016||($1.17)||($1.22)||$1.07 million||$1.28 million||View||N/A|
Earnings Estimates for Heron Therapeutics (NASDAQ:HRTX)
2017 EPS Consensus Estimate: ($3.63)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Heron Therapeutics (NASDAQ:HRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Heron Therapeutics (NASDAQ:HRTX)
Insider Ownership Percentage: 20.31%Insider Trades by Quarter for Heron Therapeutics (NASDAQ:HRTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/24/2017||Kimberly Manhard||VP||Sell||21,542||$15.33||$330,238.86|| |
|1/19/2017||Kevin C Tang||Director||Buy||2,459,016||$12.20||$29,999,995.20|| |
|8/10/2016||Robert Rosen||Insider||Sell||100,000||$23.30||$2,330,000.00|| |
|4/21/2016||Robert Rosen||President||Sell||200,000||$23.23||$4,646,000.00|| |
|6/10/2015||Kevin C Tang||Director||Buy||121,212||$24.75||$2,999,997.00|| |
|6/2/2015||Kevin C Tang||Director||Buy||150,000||$20.62||$3,093,000.00|| |
|6/1/2015||Kimberly Manhard||Director||Sell||2,708||$21.17||$57,328.36|| |
|6/25/2014||Barry D Quart||CEO||Buy||10,000||$11.75||$117,500.00|| |
|6/25/2014||Kevin C Tang||Director||Buy||510,638||$11.75||$5,999,996.50|| |
|11/20/2013||Barry D Quart||CEO||Buy||1,000,000||$0.40||$400,000.00|| |
Headline Trends for Heron Therapeutics (NASDAQ:HRTX)
Latest Headlines for Heron Therapeutics (NASDAQ:HRTX)
|Research Analysts Offer Predictions for Heron Therapeutics Inc's Q2 2017 Earnings (HRTX)|
www.americanbankingnews.com - May 15 at 7:46 AM
|Heron Therapeutics Inc (HRTX) Rating Reiterated by Noble Financial|
www.americanbankingnews.com - May 13 at 11:32 AM
|Heron Therapeutics Inc (HRTX) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - May 12 at 6:42 PM
|Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : May 12, 2017|
finance.yahoo.com - May 12 at 6:26 PM
|Heron Therapeutics Inc (HRTX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS|
www.americanbankingnews.com - May 11 at 10:04 PM
|Heron Therapeutics' (HRTX) "Buy" Rating Reaffirmed at Cantor Fitzgerald|
www.americanbankingnews.com - May 11 at 9:36 PM
|Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : May 11, 2017|
finance.yahoo.com - May 11 at 6:19 PM
|Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress|
finance.yahoo.com - May 10 at 6:34 PM
|Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate ... - Business Wire (press release)|
www.businesswire.com - May 10 at 1:33 PM
|Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - Business Wire (press release)|
www.businesswire.com - May 10 at 1:33 PM
|Heron Therapeutics reports 1Q loss|
marketbeat.com - May 10 at 8:33 AM
|Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference|
finance.yahoo.com - May 9 at 5:31 PM
|Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Heron Therapeutics (HRTX) Share Price|
www.americanbankingnews.com - May 9 at 12:50 AM
|Zacks: Brokerages Anticipate Heron Therapeutics Inc (HRTX) Will Post Quarterly Sales of $1.96 Million|
www.americanbankingnews.com - May 5 at 3:32 PM
|Heron Therapeutics Inc (HRTX) Expected to Announce Earnings of -$0.94 Per Share|
www.americanbankingnews.com - May 3 at 12:02 PM
|Heron Therapeutics (HRTX) Earns Coverage Optimism Score of 0.20|
www.americanbankingnews.com - May 3 at 1:04 AM
|Heron Therapeutics Inc (HRTX) Short Interest Up 1.5% in April|
www.americanbankingnews.com - April 30 at 4:18 PM
|Heron Therapeutics (HRTX) Receiving Somewhat Favorable Media Coverage, Report Shows|
www.americanbankingnews.com - April 29 at 11:09 PM
|Heron Therapeutics (HRTX) Earns Coverage Optimism Score of 0.28|
www.americanbankingnews.com - April 26 at 6:32 PM
|Heron Therapeutics Inc (HRTX) VP Sells $330,238.86 in Stock|
www.americanbankingnews.com - April 24 at 11:06 PM
|Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance|
finance.yahoo.com - April 24 at 5:27 PM
|Heron Therapeutics (HRTX) Earning Positive Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 23 at 11:25 AM
|Heron Therapeutics (HRTX) Receives News Sentiment Score of -0.03|
www.americanbankingnews.com - April 20 at 5:51 PM
|Heron Therapeutics Inc (HRTX) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - April 17 at 6:37 PM
|Heron Therapeutics (HRTX) Given News Sentiment Score of 0.01|
www.americanbankingnews.com - April 17 at 3:24 PM
|$2.31 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter|
www.americanbankingnews.com - April 14 at 2:21 PM
|Short Interest in Heron Therapeutics Inc (HRTX) Declines By 7.3%|
www.americanbankingnews.com - April 14 at 9:04 AM
|Heron Therapeutics (HRTX) Earns Daily News Sentiment Rating of 0.24|
www.americanbankingnews.com - April 13 at 3:20 PM
|Zacks: Brokerages Expect Heron Therapeutics Inc (HRTX) to Post -$0.94 EPS|
www.americanbankingnews.com - April 12 at 7:49 AM
|Heron Therapeutics Inc (HRTX) Rating Reiterated by Jefferies Group LLC|
www.americanbankingnews.com - April 10 at 5:12 PM
|Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : April 5, 2017|
finance.yahoo.com - April 7 at 10:19 AM
|HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - April 3 at 3:06 PM
|FY2019 Earnings Forecast for Heron Therapeutics Inc Issued By Leerink Swann (HRTX)|
www.americanbankingnews.com - March 23 at 1:38 PM
|Heron Therapeutics Inc (HRTX) Earns "Buy" Rating from Aegis|
www.americanbankingnews.com - March 23 at 8:53 AM
|Heron Therapeutics (HRTX) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow|
seekingalpha.com - March 22 at 10:59 PM
|Heron Therapeutics Inc (HRTX) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - March 22 at 12:04 PM
|Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference|
finance.yahoo.com - March 13 at 5:40 PM
|Heron Therapeutics (HRTX) Presents At Cowen and Company 37th Annual Health Care Conference|
seekingalpha.com - March 8 at 6:32 PM
|Heron Therapeutics Inc (HRTX) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 8 at 1:31 AM
|HERON THERAPEUTICS, INC. /DE/ Financials|
finance.yahoo.com - March 1 at 5:24 PM
|Coverage initiated on Heron Therapeutics by Needham|
finance.yahoo.com - February 27 at 6:50 PM
|Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress - Business Wire (press release)|
www.businesswire.com - February 25 at 12:05 AM
|Heron Therapeutics (HRTX) Announces Inclusion of SUSTOL ER Injection in NCCN Antiemesis Guidelines|
www.streetinsider.com - February 24 at 10:32 AM
|Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines|
us.rd.yahoo.com - February 24 at 10:32 AM
|8:02 am Heron Therapeutics announces the inclusion of Sustol extended-release injection as part of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017|
us.rd.yahoo.com - February 24 at 10:32 AM
|Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress|
finance.yahoo.com - February 23 at 5:46 PM
|HERON THERAPEUTICS, INC. /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements|
biz.yahoo.com - February 23 at 5:46 PM
|Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference|
us.rd.yahoo.com - February 8 at 6:22 PM
|LifeSci Capital Initiates Coverage of Heron Therapeutics|
finance.yahoo.com - February 7 at 7:02 PM
|Heron Therapeutics Announces Underwriters' Exercise in Full of Option to Purchase Additional Shares - Business Wire (press release)|
www.businesswire.com - January 31 at 6:28 PM
Heron Therapeutics (HRTX) Chart for Tuesday, May, 23, 2017